Irritable bowel syndrome (IBS) remains one of the most common gastrointestinal disorders
seen by clinicians in both primary and secondary care. Since publication of the last British …

Constipation is the most common adverse event (AE) of opioid therapy. This multicenter,
phase 2 study evaluated the efficacy and safety of linaclotide in treating opioid-induced …

Introduction: Linaclotide, a guanylate cyclase C agonist that improves the symptoms of
irritable bowel syndrome with predominant constipation (IBS-C), has been recently …

Background How variations predicted by pharmacogenomic testing to alter drug metabolism
and therapeutic response affect outcomes for patients with disorders of gut‐brain interaction …

I read with great interest the report from Carbone et al1 of the pragmatic open DOMINO trial
of low FODMAP diet (in addition to traditional dietary advice) compared with the spasmolytic …

In the current issue of GASTROENTEROLOGY, el-Salhy et al.(1) report durability of efficacy
on IBS symptoms and quality of life (QOL) 2 and 3 years after duodenally-administered fecal …

Background. Irritable bowel syndrome (IBS) is a common chronic gut‐brain interaction
disorder with limited effective treatment options. Intestinal adsorbents have a high …

Objectives We evaluated the effectiveness and tolerability of linaclotide, a minimally
absorbed guanylate cyclase-C agonist, in patients with irritable bowel syndrome with …

Despite advancements in pain medicine, management, chronic abdominal visceral
discomfort remains a substantial concern for both patients and physicians. Standard …

Functional dyspepsia (FD) is a common functional gastrointestinal disorder with a major
social and economic impact in patients (63, 305). Based on symptom pattern, the Rome III …